4.7 Article

Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses

Journal

CELL DISCOVERY
Volume 8, Issue 1, Pages -

Publisher

SPRINGERNATURE
DOI: 10.1038/s41421-022-00401-6

Keywords

-

Categories

Funding

  1. National Natural Science Foundation of China [31771008, 32022037]
  2. National Major Science and Technology Projects of China [2017ZX10202102, 2018ZX10301403]
  3. Strategic Priority Research Program of the Chinese Academy of Sciences [XDB29010101]
  4. Hundred Talent Program of Shanghai Municipal Health Commission [2018BR08]
  5. Chinese Academy of Medical Sciences [2019PT350002]
  6. SARS-CoV-2 Emergency Project of the Science and Technology Department of Zhejiang Province [2020C03129]
  7. China Postdoctoral Science Foundation [2020M681937]
  8. National Postdoctoral Program for Innovative Talents of China [BX20200304]
  9. Leading Innovative and Entrepreneur Team Introduction Program of Hangzhou
  10. Tencent Foundation
  11. Westlake Education Foundation

Ask authors/readers for more resources

The emergence of SARS-CoV-2 variants of concern has raised alarm due to their increased infectivity, transmissibility, and decreased sensitivity to antibodies and vaccines. This study introduces a bispecific antibody, G9, that can neutralize a wide range of variants, including the Omicron variant.
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) has aroused concerns over their increased infectivity and transmissibility, as well as decreased sensitivity to SARS-CoV-2-neutralizing antibodies (NAbs) and the current coronavirus disease 2019 (COVID-19) vaccines. Such exigencies call for the development of pan-sarbecovirus vaccines or inhibitors to combat the circulating SARS-CoV-2 NAb-escape variants and other sarbecoviruses. In this study, we isolated a broadly NAb against sarbecoviruses named GW01 from a donor who recovered from COVID-19. Cryo-EM structure and competition assay revealed that GW01 targets a highly conserved epitope in a wide spectrum of different sarbecoviruses. However, we found that GW01, the well-known sarbecovirus NAb S309, and the potent SARS-CoV-2 NAbs CC12.1 and REGN10989 only neutralize about 90% of the 56 tested currently circulating variants of SARS-CoV-2 including Omicron. Therefore, to improve efficacy, we engineered an IgG-like bispecific antibody GW01-REGN10989 (G9) consisting of single-chain antibody fragments (scFv) of GW01 and REGN10989. We found that G9 could neutralize 100% of NAb-escape mutants (23 out of 23), including Omicron variant, with a geometric mean (GM) 50% inhibitory concentration of 8.8 ng/mL. G9 showed prophylactic and therapeutic effects against SARS-CoV-2 infection of both the lung and brain in hACE2-transgenic mice. Site-directed mutagenesis analyses revealed that GW01 and REGN10989 bind to the receptor-binding domain in different epitopes and from different directions. Since G9 targets the epitopes for both GW01 and REGN10989, it was effective against variants with resistance to GW01 or REGN10989 alone and other NAb-escape variants. Therefore, this novel bispecific antibody, G9, is a strong candidate for the treatment and prevention of infection by SARS-CoV-2, NAb-escape variants, and other sarbecoviruses that may cause future emerging or re-emerging coronavirus diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available